- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Krystexxa has been withdrawn at the request of the marketing-authorisation holder.
Krystexxa : EPAR - Summary for the public
English (EN) (521.09 KB - PDF)
български (BG) (1.13 MB - PDF)
español (ES) (1.02 MB - PDF)
čeština (CS) (1.07 MB - PDF)
dansk (DA) (987.73 KB - PDF)
Deutsch (DE) (988.53 KB - PDF)
eesti keel (ET) (1.03 MB - PDF)
ελληνικά (EL) (1.22 MB - PDF)
français (FR) (990.13 KB - PDF)
italiano (IT) (975.29 KB - PDF)
latviešu valoda (LV) (1.15 MB - PDF)
lietuvių kalba (LT) (1022.33 KB - PDF)
magyar (HU) (1.06 MB - PDF)
Malti (MT) (1.13 MB - PDF)
Nederlands (NL) (987.81 KB - PDF)
polski (PL) (1.07 MB - PDF)
português (PT) (1.02 MB - PDF)
română (RO) (1020.33 KB - PDF)
slovenčina (SK) (1.07 MB - PDF)
slovenščina (SL) (1.12 MB - PDF)
Suomi (FI) (985.93 KB - PDF)
svenska (SV) (983.73 KB - PDF)
Product information
Krystexxa : EPAR - Product Information
English (EN) (1.41 MB - PDF)
български (BG) (2.54 MB - PDF)
español (ES) (1.41 MB - PDF)
čeština (CS) (2.15 MB - PDF)
dansk (DA) (1.4 MB - PDF)
Deutsch (DE) (1.44 MB - PDF)
eesti keel (ET) (1.4 MB - PDF)
ελληνικά (EL) (2.63 MB - PDF)
français (FR) (1.48 MB - PDF)
hrvatski (HR) (1.48 MB - PDF)
íslenska (IS) (1.43 MB - PDF)
italiano (IT) (1.5 MB - PDF)
latviešu valoda (LV) (2.21 MB - PDF)
lietuvių kalba (LT) (1.54 MB - PDF)
magyar (HU) (2.18 MB - PDF)
Malti (MT) (2.27 MB - PDF)
Nederlands (NL) (1.42 MB - PDF)
norsk (NO) (1.41 MB - PDF)
polski (PL) (2.18 MB - PDF)
português (PT) (1.45 MB - PDF)
română (RO) (1.48 MB - PDF)
slovenčina (SK) (2.16 MB - PDF)
slovenščina (SL) (2.13 MB - PDF)
Suomi (FI) (1.41 MB - PDF)
svenska (SV) (1.41 MB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Krystexxa : EPAR - All Authorised presentations
English (EN) (931.95 KB - PDF)
български (BG) (1.03 MB - PDF)
español (ES) (932.55 KB - PDF)
čeština (CS) (985.9 KB - PDF)
dansk (DA) (991.86 KB - PDF)
Deutsch (DE) (932.25 KB - PDF)
eesti keel (ET) (932.05 KB - PDF)
ελληνικά (EL) (527.69 KB - PDF)
français (FR) (932.36 KB - PDF)
íslenska (IS) (932.41 KB - PDF)
italiano (IT) (991.66 KB - PDF)
latviešu valoda (LV) (987.38 KB - PDF)
lietuvių kalba (LT) (959.88 KB - PDF)
magyar (HU) (969.58 KB - PDF)
Malti (MT) (1.02 MB - PDF)
Nederlands (NL) (991.98 KB - PDF)
norsk (NO) (932.37 KB - PDF)
polski (PL) (1.02 MB - PDF)
português (PT) (932.67 KB - PDF)
română (RO) (959.71 KB - PDF)
slovenčina (SK) (1.01 MB - PDF)
slovenščina (SL) (969.12 KB - PDF)
Suomi (FI) (991.27 KB - PDF)
svenska (SV) (992.26 KB - PDF)
Product details
- Name of medicine
- Krystexxa
- Active substance
- pegloticase
- International non-proprietary name (INN) or common name
- pegloticase
- Therapeutic area (MeSH)
- Gout
- Anatomical therapeutic chemical (ATC) code
- M04AX02
Pharmacotherapeutic group
Antigout preparationsTherapeutic indication
Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
Authorisation details
- EMA product number
- EMEA/H/C/002208
- Marketing authorisation holder
- Crealta Pharmaceuticals Ireland Limited
Commercial House
Millbank Business Park
Lower Lucan Road
Lucan, Co.
Dublin
Ireland - Marketing authorisation issued
- 08/01/2013
- Revision
- 3
Assessment history
Krystexxa : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (1005.03 KB - PDF)
Krystexxa-PSUSA-00010046-201501 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
English (EN) (1003.14 KB - PDF)
Krystexxa : EPAR - Public assessment report
English (EN) (5.41 MB - PDF)
CHMP summary of positive opinion for Krystexxa
English (EN) (970.17 KB - PDF)
More information on Krystexxa
Public statement on Krystexxa: Withdrawal of the marketing authorisation in the European Union
English (EN) (57.86 KB - PDF)